Noile-Immune Biotech (TSE:4893) Total Liabilities : 円107.2 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Noile-Immune Biotech Total Liabilities?

Noile-Immune Biotech's Total Liabilities for the quarter that ended in Mar. 2024 was 円107.2 Mil.

Noile-Immune Biotech's quarterly Total Liabilities declined from Sep. 2023 (円201.75 Mil) to Dec. 2023 (円91.49 Mil) but then increased from Dec. 2023 (円91.49 Mil) to Mar. 2024 (円107.22 Mil).

Noile-Immune Biotech's annual Total Liabilities increased from Dec. 2021 (円85.72 Mil) to Dec. 2022 (円340.42 Mil) but then declined from Dec. 2022 (円340.42 Mil) to Dec. 2023 (円91.49 Mil).

Noile-Immune Biotech Total Liabilities Historical Data

The historical data trend for Noile-Immune Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noile-Immune Biotech Total Liabilities Chart

Noile-Immune Biotech Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Liabilities

75.88

85.72

340.42

91.49

Noile-Immune Biotech Quarterly Data
	Dec20	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial				-	198.64	201.75	91.49	107.22

Noile-Immune Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Noile-Immune Biotech's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	86.26	+	(0	+	5.234
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	91.5

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	5778.946	-	5687.452
	=	91.5

Noile-Immune Biotech's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	101.983	+	(0	+	5.234
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	107.2

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	5456.992	-	5349.775
	=	107.2

Noile-Immune Biotech Total Liabilities Related Terms

Thank you for viewing the detailed overview of Noile-Immune Biotech's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Noile-Immune Biotech (TSE:4893) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noile-Immune Biotech Inc (TSE:4893) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

2-12-10 Shiba-Daimon, Minato-ku, Tokyo, JPN, 105-0012

Website

https://www.noile-immune.com

Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.

Noile-Immune Biotech (TSE:4893) Headlines

No Headlines